Ajax’s lead asset is AJ1-11095, a once-daily Type II JAK2 inhibitor taken orally, which is currently in a Phase I trial.
Eli Lilly outlays $2.3bn to acquire blood cancer specialist Ajax Therapeutics
Ajax’s lead asset is AJ1-11095, a once-daily Type II JAK2 inhibitor taken orally, which is currently in a Phase I trial.
A recent poll shows Democrats holding a 10-point lead over Republicans in the upcoming elections.
After submitting plans to cut 114 jobs tied to its U.S. headquarters in New Jersey in March, Novartis late last month added a handful of additional …
The only two national holidays that Fairfax is not observing are Veterans Day and Columbus Day.
Thousands of patients will be offered a new injectable form of an immunotherapy drug that takes minutes.